The best drug supplement for obesity treatment: a systematic review and network meta-analysis.
The best drug supplement for obesity treatment: a systematic review and network meta-analysis.
复制标题
治疗肥胖症的最佳药物补充：系统性综述和网络荟萃分析。
DOI：
10.1186/s13098-021-00733-5
复制
发表时间：
2021-10-18
影响因子：
4.8
通讯作者：
Shohaimi S
中科院分区：
文献类型：
--
作者：
Salari N;Jafari S;Darvishi N;Valipour E;Mohammadi M;Mansouri K;Shohaimi S
肥胖是一种复杂的疾病，在世界范围内日益流行。肥胖治疗有不同的体重管理选择，包括饮食控制、运动、手术和药物治疗。药物总是与不同人的不同反应相关联。更安全、更有效、副作用更少的药物对任何临床状况都是有价值的。在本系统综述和网络荟萃分析中，比较了不同的抗肥胖药物，以确定最有效的药物。通过检索SID、MagIran、ProQuest、PubMed、Science Direct、Scopus、Web of Science （WoS）和谷歌Scholar等国内外数据库提取所有相关研究，检索时间截止至2020年10月。最后，对包含14种不同药物补充剂的11项剩余研究进行荟萃分析。以95%置信区间（CI）计算标准化平均差（SMD），以评估各治疗组与安慰剂相比的效果。随机效应模型用于评价个别研究对最终结果的影响。网络的异质性和不兼容性分别通过Cochran 's Q和Higgins I2以及净热量图进行评估。采用R软件进行数据分析。我们的研究结果显示，芬特明15.0 mg +托吡酯92.0 mg、芬特明7.5 mg +托吡酯46.0 mg、普兰林肽、纳曲酮+安非他酮32和利拉鲁肽干预组的平均效果显著，SMD效应大小分别为- 9.1、- 7.4、- 6.5、- 5.9和- 5.35。本研究的目的是比较不同药物对肥胖患者的减肥效果。与安慰剂治疗相比，最有效的减肥药物分别是芬特明和托吡酯、普兰林肽、纳曲酮、安非他酮和利拉鲁肽。这项研究为抗肥胖药物提供了新的见解，并希望为未来的肥胖管理和治疗研究提供新的思路。
Obesity is a complex disease with an increasing prevalence worldwide. There are different weight-management options for obesity treatment, including dietary control, exercise, surgery, and medication. Medications are always associated with different responses from different people. More safety and efficacy of drugs with fewer side effects are valuable for any clinical condition. In this systematic review and network meta-analysis, different anti-obesity drugs are compared to identify the most effective drug. All relevant studies were extracted by searching national and international databases of SID, MagIran, ProQuest, PubMed, Science Direct, Scopus, Web of Science (WoS), and Google Scholar without time limit until October 2020. Finally, the meta-analysis was performed with the 11 remaining studies containing 14 different drug supplements. The standardized mean difference (SMD) was calculated at a 95% confidence interval (CI) to evaluate the effects of each treatment group compared with placebo. A random-effect model was used to evaluate the effect of individual studies on the final result. Heterogeneity and incompatibility of the network were assessed by Cochran’s Q and Higgins I2, and the Net Heat chart, respectively. Data analysis was performed using R software. Our results showed that there were significant mean effects in people intervened with Phentermine 15.0 mg + Topiramate 92.0 mg, Phentermine 7.5 mg + Topiramate 46.0 mg, Pramlintide, Naltrexone + Bupropion 32, and Liraglutide, with SMD effects size = − 9.1, − 7.4, − 6.5, − 5.9, − 5.35, respectively. This study was performed to compare the effect of different drugs used for weight loss in obese patients. The most effective drugs for weight loss were phentermine and topiramate, pramlintide, naltrexone, bupropion, and liraglutide compared to placebo treatment, respectively. This study provides new insights into anti-obesity drugs and hopes to shed new light on future research to manage and treat obesity.
登录
查看更多内容
影响因子：
1.6
作者：
Farsi, Deema J.;Elkhodary, Heba M.;Alolayyan, Mohammed A.
通讯作者：
Alolayyan, Mohammed A.
影响因子：
168.9
作者：
Greenway, Frank L.;Fujioka, Ken;Dunayevich, Eduardo
通讯作者：
Dunayevich, Eduardo
影响因子：
4.9
作者：
Fujioka, K.;Plodkowski, R.;Greenway, F. L.
通讯作者：
Greenway, F. L.
影响因子：
5.8
作者：
Hanefeld, M;Sachse, G
通讯作者：
Sachse, G
影响因子：
5.1
作者：
Danne, Thomas;Biester, Torben;Kordonouri, Olga
通讯作者：
Kordonouri, Olga